The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has established the Drug-Induced Liver Injury Network (DILIN) to collect and analyze cases of severe liver injury caused by prescription drugs, over-the-counter drugs, and alternative medicines, such as herbal products and supplements. Currently, DILIN is conducting 2 registry studies:

• Retrospective Study, to establish a nationwide registry of people who have experience past liver injury due to prescription drugs and alternative agents like herbal and dietary supplements. This is an ongoing registry that has been active since 1994. Since this is a retrospective registry, it is possible participation can be done remotely and not necessarily on-site. Please contact one of the DILIN sites for more information on participation.

Prospective Study, to establish a nationwide registry of people who have experienced liver injury within the past 6 months after using certain drugs or alternative products.

Causality Process and Web Application, The diagnosis of drug-induced liver injury relies on evidence linking the injury to a specific drug or agent. DILIN uses “expert opinion” to determine the degree of association between the implicated medication(s) and the liver injury. This process is identified as DiLiN Causality Case Adjudication which is the DiLiN project primary Endpoint.